Alignment Healthcare (ALHC) Q3 2024: Membership Surges 58% as Stars Ratings Lock in Multi-Year Margin Tailwind

October 29, 2024 | By EarningsIQ Research

Alignment Healthcare delivered its highest-ever quarterly growth, with membership up 58% and Stars ratings cementing a multi-year funding advantage. The company’s disciplined portfolio approach and scalable clinical model are driving both outperformance and future margin expansion, even as sector peers struggle with CMS headwinds. Management guides to continued profitable growth in 2025, leveraging operational leverage and Stars tailwinds to expand margins and fuel geographic expansion.

Summary

• Stars Ratings Outperformance: Alignment’s Stars ratings advantage is translating into durable funding and margin upside.
• Operational Scale: Cost leverage from rapid membership growth is driving SG&A efficiency and profitability.
• Margin Expansion Focus: 2025 strategy pivots toward margin gains while sustaining double-digit growth.

Business Overview

Alignment Healthcare is a technology-enabled Medicare Advantage (MA) plan operator focused on delivering population health management for seniors through its integrated data, health plan, and clinical ecosystem. The company generates revenue primarily from government payments tied to MA plan enrollment and performance metrics, with its business concentrated in California and growing in Nevada and North Carolina. Major segments include its core MA plans, ACO REACH, and a proprietary Care Anywhere clinical model designed to control utilization and improve member outcomes.

Performance Analysis

Q3 2024 marked a record-setting quarter for Alignment, with health plan membership reaching 182,300—up 58% year-over-year—and revenue growing 52%. This surge was driven by disciplined bidding, Stars ratings leadership, and successful execution of a portfolio strategy focused on profitable markets. Excluding ACO REACH, revenue growth was even stronger, highlighting the core plan’s momentum. Adjusted gross profit and EBITDA both landed at the high end of guidance, despite the operational complexity of onboarding more new members in a single year than in the prior three combined.

Cost control and operational leverage were evident in SG&A as a percentage of revenue dropping from 16.2% to 10.8% year-over-year, a 540 basis point improvement. This reflects both scale benefits and the lapping of prior-year investments in member experience. Medical Benefit Ratio (MBR) was modestly pressured by the influx of new members, who typically present higher initial costs, but this was offset by lower-than-expected utilization and SG&A efficiencies. The company’s ability to meet or exceed profit targets while growing at this pace is a notable outlier in a sector facing reimbursement and Stars headwinds.

• Membership Growth Engine: Alignment’s 58% membership gain outpaces the industry and underpins both current and future margin expansion.
• SG&A Leverage: Operating model scalability is driving significant cost efficiency, with SG&A as a percent of revenue at historic lows.
• Utilization Management: Inpatient admissions per thousand remained below prior-year levels, supporting gross margin stability.

With a cash balance of $381 million and no major new market launches in 2025, the company is positioned to fund organic growth and margin expansion from operations.

Executive Commentary

Strategic Positioning

1. Stars Ratings and Payment Advantage

Alignment’s Stars ratings are a core strategic lever, with 98% of members in plans rated four stars or above for 2025 and multi-year tailwinds from upcoming CMS policy changes. The California HMO contract—comprising 86% of MA membership—has held a four-star or better rating for eight years, while Nevada and North Carolina retain five-star status. As CMS shifts to reward clinical quality and health equity, Alignment’s member mix and performance position it for enhanced bonus payments and rebate funding, reinforcing its cost and benefit leadership.

2. Clinical Model and Care Anywhere

The Care Anywhere program, Alignment’s home-based care model, is driving both utilization control and member engagement, key to retention and cost management. The company is investing in provider operations, workflow automation, and performance management with Independent Physician Associations (IPAs), targeting deeper integration to improve both access and Stars scores. These operational advances are not only supporting growth but also laying the foundation for continued margin improvement and differentiation versus peers.

3. Margin Expansion and Portfolio Discipline

For 2025, Alignment is shifting its strategy to prioritize margin expansion over growth, targeting at least 20% membership growth but with greater emphasis on profitability. This is achieved through benefit reductions in line with peers, targeted investments in clinical operations, and leveraging cohort improvement as new members mature into lower-cost profiles. The company’s approach balances sustainable growth with disciplined capital allocation, enabling self-funded expansion into new geographies in future years.

4. Operational Leverage and Cost Control

SG&A as a percent of revenue is on track to reach 10.9% for the year, with further improvement targeted. The company is benefiting from economies of scale, no major new market launches in 2025, and the lapping of prior-year investment in member experience insourcing. Management is targeting a long-term goal of 10% SG&A, including depreciation and stock-based compensation, supporting ongoing margin gains.

5. Local Market Execution and Provider Partnerships

Alignment’s emphasis on local market execution and provider collaboration is enabling it to outperform in an environment where many MA plans are struggling with provider contracting and downstream risk arrangements. By internalizing more of the care management and focusing on surplus sharing with IPAs, the company is positioning itself as a preferred partner and building a model that is less reliant on traditional global capitation structures, which are under pressure as sector economics tighten.

Key Considerations

This quarter demonstrates Alignment’s ability to scale profitably while navigating sector headwinds and regulatory changes. The company’s Stars ratings and operational model are delivering both immediate and multi-year funding advantages, supporting a virtuous cycle of growth, retention, and margin expansion. Investors should weigh the following:

Key Considerations:

• Stars Ratings Tailwind: CMS policy changes and Alignment’s high-quality ratings underpin a durable funding and margin advantage into 2027 and beyond.
• Cohort Maturation Effect: As the large 2024 new member cohort matures, historical trends suggest a 300 basis point MBR improvement from year one to year two, fueling future margin gains.
• Provider Integration Strategy: Deeper integration with IPAs and automation of provider workflows aim to improve access, care coordination, and Stars scores, while reducing costs.
• SG&A Efficiency: Economies of scale and the absence of year-zero market launch costs are driving sustainable cost leverage, with further improvement targeted for 2025.
• Balanced Growth-Margin Approach: The 2025 bid cycle prioritizes margin over growth, with benefit reductions matching peers while maintaining competitive offerings through Stars and risk model advantages.

Risks

Key risks include potential regulatory shifts in MA reimbursement, competitive responses to Stars outperformance, and execution risk as the company scales clinical and provider operations. While Stars changes are currently a tailwind, any future recalibration by CMS could alter the funding landscape. Provider pushback on risk arrangements remains a sector-wide challenge, though Alignment’s model is designed to mitigate this. Retention and utilization management will be critical as new cohorts mature, and any lapses could pressure margins or disrupt the growth trajectory.

Forward Outlook

For Q4 2024, Alignment guides to:

• Health plan membership of 184,000 to 186,000
• Revenue of $663 million to $678 million
• Adjusted EBITDA range of a $10 million loss to $5 million profit

For full-year 2024, management raised membership guidance and expects:

• Revenue of $2.67 billion to $2.68 billion
• Adjusted EBITDA of a $10 million loss to $5 million profit

Management highlighted several factors that support the 2025 outlook:

• At least 20% membership growth and $40 million adjusted EBITDA in 2025
• Multi-year Stars and risk model tailwinds, with operating leverage continuing to improve

Takeaways

Alignment’s Q3 results validate the company’s differentiated MA model, with Stars ratings and operational scale driving both current outperformance and a multi-year margin expansion pathway.

• Stars Ratings Lock in Funding Advantage: Alignment’s sustained Stars leadership secures enhanced rebates and margin visibility as peers struggle with CMS cut points.
• SG&A Leverage Demonstrates Scalable Model: Rapid membership growth is translating into cost efficiencies and EBITDA profitability ahead of sector peers.
• 2025 Set Up for Margin Expansion: Balanced growth and margin strategy, alongside cohort improvement, positions Alignment to deliver on rising profit targets and self-fund future expansion.

Conclusion

Alignment Healthcare’s Q3 performance underscores its status as a top-tier MA operator, leveraging Stars ratings, operational scale, and disciplined execution to capture share and expand margins. With multi-year tailwinds and a clear path to profitable growth, Alignment is well-positioned to outperform as the MA sector undergoes structural change.

Industry Read-Through

Alignment’s outperformance and Stars ratings resilience highlight the growing divergence in the Medicare Advantage sector as CMS tightens quality and reimbursement standards. Operators with integrated clinical models, data-driven care management, and local provider alignment are gaining share, while those reliant on legacy capitation or lacking Stars advantages face funding headwinds. The shift toward population health management, operational scalability, and cohort retention is increasingly critical, with implications for MA plan bidding strategies, provider contracting, and sector consolidation. Investors should watch for further separation between high-performing MA platforms and those unable to adapt to the new regulatory and competitive paradigm.

ALHC Healthcare Medicare Advantage Population Health Stars Ratings Margin Expansion SG&A Leverage Care Anywhere